The in vivo and in vitro haemolytic activity of guaiacol glycerol ether has been investigated. Intravenous injections in concentrations of 12.5 per cent or greater produced intravascular haemolysis. The haemolysis produced was not related to the speed of injection. In vitro studies with concentrations of guaiacol glycerol ether confirmed that the critical concentration for the production of haemolysis was 12.5 per cent. Guaiacol glycerol ether has approximately one-twentieth the haemolytic activity of ortho-toluol glycerol ether (mephenesin, Myanesin).
The muscle relaxant mephenesin (ortho-toluol glycerol ether; Myanesin) has the same haemolytic effect in vivo and in vitro; concentrations greater than approximately 1 per cent cause haemolysis within a few minutes (Berger, 1950) . Guaiacol glycerol ether (trade names MY.301, Myocain, Reorganin) has less than one-quarter of the haemolytic action of mephenesin (Ginzel, Leupold-Lowenthal and Weis, 1949) , and subsequent authors have agreed that guaiacol glycerol ether may be administered intravenously in large doses with little danger of significant haemolysis (Ginzel, Mayrhofer and Chott, 1949; Marcus and Lobermeyer, 1955; Truitt and Patterson, 1957) . In vivo studies on the haemolytic activity of guaiacol glycerol ether in man have not, however, been reported. Berger, Hubbard and Ludwig (1953) added rabbit cells to various dilutions of guaiacol glycerol ether and determined, by visual comparison with a prepared standard, the time required to achieve 75 per cent haemolysis. Truitt and Patterson (1957) added heparinized blood to concentrations of guaiacol glycerol ether from 2 to 3 per cent, and measured the haemoglobin in the supernatant. Guaiacol glycerol ether was found to have 31 per cent of the haemolytic action of mephenesin. These authors also injected intravenously into dogs 4 per cent and 5 per cent solutions of guaiacol glycerol ether at a rate of approxi-461 mately 15 ml/min, and measured serum bilirubin and plasma haemoglobin. The plasma haemoglobin results are not detailed, but the authors state that the maximum observed values did not exceed the human renal threshold for haemoglobin (100 mg per cent). Mephenesin is not favoured in anaesthetic practice in Britain on account of its haemolytic effects, which have been blamed for fatalities (Pugh and Enderby, 1947; Hewer and Woolmer, 1947) and for the occurrence of thrombophlebitis (Gray, 1948) . Guaiacol glycerol ether is, however, apparently widely and successfully used on the continent of Europe, in anaesthetic practice as well as in the treatment of tetanus (Frey and Kirchner, 1959; Hodum, 1960; Mohacsi and Kosa, 1962) . Mostert (1963) has reported elsewhere on the clinical aspects of this muscle relaxant. In view of this, it was felt warranted to report the results of some studies on the haemolytic activity of this drug and its prevention.
MATERIAL AND METHODS

Patients.
Studies were carried out in 51 patients undergoing surgical operations. Patients who had received blood transfusions before or during the operation were excluded, as were patients undergoing operations involving extracorporeal circula-tion. Concentrations of MY.301 (a solution of guaiacol glycerol ether in 5 per cent laevulose) from 0.4 to 20 per cent were prepared in normal saline and injected intravenously at rates varying from 2 to 60 ml per minute, in 46 patients. In 5 patients, concentrations of Myanesin (a 10 per cent solution of mephenesin in ethyl alcohol and propylene glycol) from 0.5 to 10 per cent in normal saline were injected at rates of 5 to 20 ml/min. Blood samples for estimation of plasma haemoglobin were drawn before the injection and exactly 15 minutes later. Precautions were taken to prevent haemolysis during collection of the samples.
A wide-bore needle (18 s.w.g.) was used, and the syringe permitted to fill spontaneously with blood. The needle was then detached; 9 ml blood was added to 1 ml 3.8 per cent sodium citrate, and gently mixed.
Measurement of plasma haemoglobin.
The method used was that of Bing and Baker (1931) as modified by Dacie (1956) . The colour developed was measured in a photo-electric colorimeter, using the blue-green filter, and the haemoglobin content calculated from the standard curve.
Specimens of blood were examined for the presence of Heinz bodies by standard methods (Dacie, 1956) . In vitro studies of haemolysis.
MY.301. Various concentrations ranging from 12.5 to 20 per cent of MY.301 were prepared in buffered 0.9 per cent NaCl. To 5 ml aliquots of these solutions 0.05 ml amounts of fresh heparinized normal blood was added, mixed and allowed to stand at room temperature for 30 minutes. Gentle mixing was repeated at 15 minutes and at the end of the 30-minute period, when the tubes were centrifuged. The haemoglobin in the supernatant was then measured as oxyhaemoglobin in a photo-electric colorimeter. All samples were read against a blank containing 0.05 ml plasma diluted in 5 ml normal saline. The percentage haemolysis was calculated (100 per cent haemolysis =0.5 ml blood in 5 ml distilled water).
Laevulose. A solution of 5 per cent laevulose in distilled water was tested in the same way.
RESULTS
The results are shown in tables I and II. Significant degrees of haemolysis were produced when solutions of MY.301 of concentration of 12.5 per 45, 52, 70 22, 60 10, 24, 29, 66 34, 34 21, 67, 69, 158 40, 47, 104 23, 35, 43, 88 25, 40, 46 39 20, 24, 45 14, 26 The results of the in vitro studies are shown in figure 2 . Solutions of MY.301 of concentration greater than 12 per cent produced haemolysis. No haemolysis occurred when red cells were suspended in 5 per cent laevulose.
Heinz bodies were not present in any of the specimens examined. 
DISCUSSION
The use of MY.301 in the treatment of tetanus is well recognized (Frey and Kirchner, 1959) , particularly when facilities for artificial respiration are inadequate. Similarly MY.301 is a most useful drug in anaesthetic practice in potentiating nitrous oxide and oxygen anaesthesia by its dampening effect on reflex irritability, its lowering of muscular tone in the absence of paralysis, and its marked sedative effect. These properties are particularly desirable in patients considered to be poor risks for anaesthesia. In the absence of overdosage the only harmful effects known in man are intravascular haemolysis and thrombophlebitis.
The results of this study indicate that mephenesin and MY.301 should always be diluted to concentrations of less than 0.5 per cent mephenesin and 10 per cent MY.301 before injection. Slow injection of more concentrated solutions does not prevent haemolysis.
The haemolytic effect of guaiacol glycerol ether is approximately one-twentieth of that of mephenesin.
